Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million

HERZLIYA, Israel and CALGARY, AB, May 27, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its…